查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1627881

急性肾损伤（AKI）疾病治疗市场：预测（2025-2030）

Acute Kidney Injury (AKI) Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

急性肾损伤（AKI）疾病治疗市场预计将以 7.50% 的复合年增长率增长，从 2025 年的 20.04 亿美元增长到 2030 年的 28.75 亿美元。

全球急性肾损伤治疗市场受到急性肾损伤发生率上升的显着影响。国家肾臟基金会估计，美国约有 3700 万人患有肾臟疾病。由于老化、不良饮食习惯和大量饮酒，肾臟受损的风险正在增加。对乙酰胺酚和其他药物过量摄取、肝炎、自体免疫疾病和代谢性疾病也是导致市场爆炸的因素。此外，不断上涨的医疗保健成本和政府改善医疗保健系统的措施预计将增加市场收益。然而，透析服务的高成本和患者对长期治疗计划的依从性低正在阻碍市场扩张。

急性肾损伤治疗市场的驱动因素：

  • 与文明病增加和技术进步

急性肾损伤是一种肾功能突然暂时丧失的疾病。这种情况可能是由于糖尿病或高血压等一些潜在疾病引起的。由于人们生活方式的改变，许多疾病不断出现。典型的例子包括糖尿病、肥胖、高血压以及与肝臟和肾臟有关的疾病。世界卫生组织（WHO）估计，影响人的健康和生活品质的变数中有60%与人的生活方式有关。人们的健康受到加工食品、垃圾食物和不良饮食习惯的影响。此外，缺乏运动或缺乏身体活动会增加消化不良和随后的急性肾损伤的风险。

人们对毒品、酒精、吸烟等成瘾，这些都会对健康产生负面影响。缺乏身体活动和缺乏运动也会增加消化不良和相关急性肾损伤的可能性。例如，国际肾臟病学会估计全球每年发生超过 1,330 万例急性肾损伤病例。此外，全球整体每年有 170 万人死于急性肾损伤。在美国，大约 1% 的住院患者发生 AKI。

此外，超过 50% 的加护病房(ICU) 患者会发生 AKI，约 1% 的普通外科病例会在术后 30 天内发生 AKI。此外，根据美国国家糖尿病、消化和肾臟疾病研究所的 2023 年报告，每 1,000 名美国中有 2 人患有终末期肾病，其中 71% 依赖透析，29% 需要接受肾臟移植。随着肾臟疾病的流行，对准确有效治疗的需求不断增加。

急性肾损伤（AKI）疾病治疗市场的地理前景：

  • 急性肾损伤治疗市场分为全球五个地区。

北美急性肾损伤疾病治疗市场分为美国、加拿大和墨西哥，预计在预测期内将以显着的复合年增长率成长。由于美国糖尿病盛行率较高，急性肾损伤患者数量不断增加。据美国疾病管制与预防中心 (CDC) 称，AKI 是美国的重大公共卫生问题，每年影响超过 50 万人，并导致超过 10 万人死亡。 AKI 也与医疗保健费用增加有关，在美国，每年因 AKI 导致的住院费用估计达 100 亿美元。此外，越来越多地采用创新治疗方法，例如肾臟替代疗法（RRT），其中包括血液透析机和腹膜透析。这些治疗方法变得越来越广泛和负担得起，使更多的患者能够获得他们需要的治疗。

此外，AKI 不同病因的盛行率将指南AKI 治疗市场的未来研究和发展。例如，由于尿路阻塞是 AKI 的重要原因，药物开发公司可能有机会专注于开发治疗方法来解决这种情况，特别是患有良性前列腺增生的老年男性。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业所采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中释放新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业/市场考量、商机评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、监管影响、新产品开发、竞争讯息

调查范围

  • 2022年至2030年历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争定位、策略和市场占有率分析
  • 区域收益成长和预测分析，包括细分市场和国家
  • 公司概况（尤其是重大发展）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章急性肾衰竭疾病治疗市场：依组成部分

  • 介绍
  • 治疗
    • 药品
    • 透析
  • 诊断
    • 尿液检查
    • 验血
    • 肾丝球过滤率 (GFR)
    • 影像检查
    • 切片检查

第六章 急性肾损伤疾病治疗市场：依 RRT 型分类

  • 介绍
  • 连续的
  • 间歇性的

第七章急性肾损伤疾病治疗市场：地区

  • 介绍
  • 北美洲
    • 按成分
    • 按 RRT 类型
    • 按国家/地区
  • 南美洲
    • 按成分
    • 按 RRT 类型
    • 按国家/地区
  • 欧洲
    • 按成分
    • 按 RRT 类型
    • 按国家/地区
  • 中东/非洲
    • 按成分
    • 按 RRT 类型
    • 按国家/地区
  • 亚太地区
    • 按成分
    • 按 RRT 类型
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Exponential Biotherapies, Inc.
  • Nikkiso America, Inc.
  • Am-Pharma
  • Renalguard Solutions, Inc.
  • Angion Biomedica Corp.
  • Thrasos Therapeutics Inc.
  • Atoxbio
  • Sentien Biotechnologies, Inc
简介目录
Product Code: KSI061612284

The acute kidney injury (AKI) disease treatment market is predicted to grow at a CAGR of 7.50% from US$2.004 billion in 2025 to US$2.875 billion by 2030.

The global market for acute renal injury treatment is significantly influenced by the rising incidence of acute kidney damage. The National Kidney Foundation estimates that kidney illnesses impact about 37 million people in the US. Kidney injury risk has increased as a result of an aging population, poor diet, and heavy alcohol use. Acetaminophen and other drug overdoses, hepatitis, autoimmune disorders, and metabolic diseases are other causes contributing to the market's explosive expansion. Additionally, it is projected that rising healthcare costs and government measures to improve the healthcare system will boost market revenue. However, the market expansion is being hampered by the high cost of dialysis services and the low compliance from patients for long-term treatment plans.

Acute kidney injury disease treatment market drivers:

  • Increase in lifestyle-related diseases and technological advancements.

Acute kidney injury results in sudden and temporary loss of the function of the kidney. This could occur due to several underlying diseases like diabetes and high blood pressure. A slew of diseases is cropping up due to the changing lifestyles of people. Some of the prominent examples are diabetes, obesity, hypertension, and other liver or kidney-related diseases. The World Health Organisation estimates that 60% of the variables affecting a person's health and quality of life are related to their way of living. People's health is being impacted by processed and junk food as well as poor eating habits. Additionally, a lack of exercise and movement increases the risk of dyspepsia and subsequent acute renal damage.

People are developing addictions to drugs, alcohol, and smoking, all of which have detrimental effects on their health. Lack of physical movement and exercise is also increasing the likelihood of indigestion, and consequent acute kidney injuries. People are getting addicted to alcohol, smoking, and drugs which also have adverse implications for their health. For instance, the International Society of Nephrology estimates that there are over 13.3 million cases of acute renal damage each year throughout the world. Globally, acute renal damage also results in 1.7 million deaths each year. AKI is present in about 1% of hospitalized patients in the United States.

Moreover, AKI occurs in more than 50% of patients in intensive care units (ICU) and occurs within 30 days of surgery in about 1% of general surgical cases. Additionally, according to the 2023 report of the National Institute of Diabetes and Digestive and Kidney Diseases, 2 in 1000 Americans have end-stage kidney illness, with 71% relying on dialysis and 29% receiving a kidney transplant. The need for precise and effective treatment is growing along with the prevalence of renal disorders.

Acute kidney injury (AKI) disease treatment market geographical outlook:

  • The acute kidney injury disease treatment market is segmented into five regions worldwide

The North American AKI disease treatment market has been segmented into the United States, Canada, and Mexico and is estimated to grow at a significant CAGR during the forecast period. The high prevalence of diabetes in the U.S. is increasing the number of people with acute kidney injury. According to the Centers for Disease Control and Prevention (CDC), AKI is a significant public health problem in the United States, affecting over 500,000 people each year and resulting in more than 100,000 deaths. AKI is also associated with increased healthcare costs, with hospitalizations for AKI costing an estimated $10 billion annually in the US. Moreover, there is increasing adoption of innovative treatment options, such as renal replacement therapies (RRTs), which include hemodialysis and peritoneal dialysis. These treatments are becoming more widely available and affordable, allowing more patients to access the care they need.

Furthermore, the prevalence of the various causes of AKI can guide future research and development in the AKI treatment market. For instance, given that urinary tract obstruction is a significant cause of AKI, there may be an opportunity for drug developers to focus on developing therapies that address this condition, especially in older men with benign prostatic hypertrophy.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Acute kidney injury disease treatment market is segmented and analyzed as follows:

By Component

  • Treatment
  • Drug Type
  • Isotonic Solution
  • Antibiotic
  • Others
  • Dialysis
  • Diagnosis
  • Urine Test
  • Blood Test
  • Glomerular Filtration Rate (GFR)
  • Imaging Test
  • Biopsy

By Type of RRT

  • Continuous
  • Intermittent

By Geography

  • North America

By Component

By Type of RRT

By Country

  • USA
  • Canada
  • Mexico
  • South America

By Component

By Type of RRT

By Country

  • Brazil
  • Argentina
  • Others
  • Europe

By Component

By Type of RRT

By Country

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa

By Component

By Type of RRT

By Country

  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific

By Component

By Type of RRT

By Country

  • China
  • Japan
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY COMPONENT

  • 5.1. Introduction
  • 5.2. Treatment
    • 5.2.1. Drug Type
      • 5.2.1.1. Isotonic Solution
      • 5.2.1.2. Antibiotic
      • 5.2.1.3. Others
    • 5.2.2. Dialysis
  • 5.3. Diagnosis
    • 5.3.1. Urine Test
    • 5.3.2. Blood Test
    • 5.3.3. Glomerular Filtration Rate (GFR)
    • 5.3.4. Imaging Test
    • 5.3.5. Biopsy

6. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY TYPE OF RRT

  • 6.1. Introduction
  • 6.2. Continuous
  • 6.3. Intermittent

7. ACUTE KIDNEY INJURY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Component
    • 7.2.2. By Type of RRT
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Component
    • 7.3.2. By Type of RRT
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Component
    • 7.4.2. By Type of RRT
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. France
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Component
    • 7.5.2. By Type of RRT
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Israel
      • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Component
    • 7.6.2. By Type of RRT
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. South Korea
      • 7.6.3.4. India
      • 7.6.3.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Exponential Biotherapies, Inc.
  • 9.2. Nikkiso America, Inc.
  • 9.3. Am-Pharma
  • 9.4. Renalguard Solutions, Inc.
  • 9.5. Angion Biomedica Corp.
  • 9.6. Thrasos Therapeutics Inc.
  • 9.7. Atoxbio
  • 9.8. Sentien Biotechnologies, Inc